Biomodex Thrombotech Synthetic Clot Product Launched for Use in Neurovascular Training

October 18, 2021—Biomodex announced the launch of Thrombotech, a hydrogel-based synthetic clot product that can be used for neurovascular training using the company’s Evias Plus training solution for the treatment of ischemic stroke. The Thrombotech technology is intended to benefit medical device companies that are developing new devices for thrombectomies as well as for fellows who are training for these complex emergency procedures.

Biomodex is introducing Thrombotech at the 2021 Congress of Neurological Surgeons annual meeting held October 18-20 in Austin, Texas. Based in Boston, Massachusetts, and Paris, France, Biomodex is focused on biorealistic haptic simulators for physician training and rehearsals.

According to the company, Thrombotech mimics the density and texture of an actual human blood clot. It can be inserted into a Biomodex three-dimensional–printed blood vessel cartridge that plugs into the Evias Plus station. Physicians can then practice retrieving the clot using aspiration and mechanical thrombectomy techniques. A distal clot filter allows physicians to see if they effectively retrieved the clot.

Thrombotech is available in three textures: soft, medium, and hard. Soft mimics red blood cell– (RBC–) rich clots, medium mimics an RBC/fibrin clot, and hard mimics a fibrin-rich clot.